Browse EX-10 agreements

ASSET REPRESENTATIONS REVIEW AGREEMENT

among

GM FINANCIAL CONSUMER AUTOMOBILE RECEIVABLES TRUST 2026-4,

Issuer

AMERICREDIT FINANCIAL SERVICES, INC.

D/B/A GM FINANCIAL,

Servicer

and

CLAYTON FIXED INCOME SERVICES LLC,

Asset Representations Reviewer

Dated as of October 14, 2026

---

TABLE OF CONTENTS

| | | | | | | | | | | ------------------------------------------------------- | - | ------------ | : | ----------------------------------------------------------- | - | - | -: | - | | | | | | | | | | | | ARTICLE I DEFINITIONS | | | | | | | 1 | |

…

** **

Amended and Restated Asset Purchase Agreement

** **

By and Among

** **

GES Acquisition Corp.;

** **

**Global Arena Holding, Inc.; **

** **

**Global Election Services, Inc. **

** **

and

** **

Easterly CV VI LLC

** **

** **

TABLE OF CONTENTS

** **

…

SERIES A CONVERTIBLE PREFERRED 
STOCK CONVERSION AGREEMENT

This Series A Convertible Preferred Stock Conversion Agreement (this “Agreement”) is entered into as of [•] [•], 2026 by and between AquaBounty Technologies, Inc., a Delaware corporation (the “Company”), and the holder identified on the signature page hereto (the “Holder”).

| | |

…

SERIES B CONVERTIBLE PREFERRED 
STOCK CONVERSION AGREEMENT

This Series B Convertible Preferred Stock Conversion Agreement (this “Agreement”) is entered into as of [•] [•], 2026 by and between AquaBounty Technologies, Inc., a Delaware corporation (the “Company”), and the holder identified on the signature page hereto (the “Holder”).

| | |

…

---

Exhibit 10.2

Execution Version

JAMES C. CLEMMER

CONSULTING AGREEMENT

THIS CONSULTING AGREEMENT (the “Agreement”) is entered into effective as of November 2, 2026 (the “Effective Date”), by and between AngioDynamics, Inc., a Delaware corporation (the “Company”), on the one hand, and James C. Clemmer, an individual (the “Consultant”), on the other hand.

WHEREAS, Consultant currently serves as the President and Chief Executive Officer of the Company;

WHEREAS, Consultant and the Company entered into that certain Transition and Retirement Agreement (the “Transition Agreement”), dated as of January 2, 2026, pursuant to which, on the earlier of (i) the appointment of a successor in the role of Chief Executive Officer of the Company and (ii) November 30, 2026, Consultant shall retire as President and Chief Executive Officer of the Company and its subsidiaries and shall transition to the role of consultant to the Company;

WHEREAS, the Company appointed a new President and Chief Executive Officer effective as of November 2, 2026; and

…

---

Exhibit 10.1

Execution Version

EMPLOYMENT AGREEMENT

This Employment Agreement (the “Agreement”) is entered into by and between AngioDynamics, Inc, a Delaware corporation (the “Company”) and Eric Honroth (“Executive”) (together, the “Parties” and individually, a “Party”).

WHEREAS, Executive wishes to be employed by the Company, and the Company wishes to secure the employment of Executive, under the terms and conditions described below.

NOW THEREFORE, in consideration of the foregoing and in consideration of the mutual promises and agreements contained herein, the Parties hereto agree as follows:

1.           Position; Location.

…

---

Exhibit 10.3

Form of AngioDynamics Retention and Severance Letter Agreement

October 5, 2026

Personal and Confidential

[Employee Name]

[Address]

Re:	AngioDynamics Retention Incentive Opportunity

Dear [Name]:

Given your critical role, skills and knowledge, your efforts on behalf of AngioDynamics are particularly important at this time. Therefore, on behalf of the AngioDynamics Board of Directors, the Company is offering you a retention incentive and severance benefit beyond your regular compensation to recognize your continued commitment to providing critical leadership to the Company during this period of transition.

Specifically, AngioDynamics is offering you the opportunity to receive additional severance benefits as a result of your continued retention as an employee through the transition to a new Chief Executive Officer as set forth below:

…

Execution Version

FIRST AMENDMENT TO CREDIT AGREEMENT

This FIRST AMENDMENT TO CREDIT AGREEMENT (this “Amendment”), dated as of October 2, 2026 (the “First Amendment Effective Date”), is by and among TETRA TECHNOLOGIES, INC., a Delaware corporation (the “Borrower”), the other Loan Parties party hereto, the Lenders party hereto, and SILVER POINT FINANCE, LLC, as Administrative Agent (in such capacity, the “Administrative Agent”).

WITNESSETH:

WHEREAS, the Borrower entered into that certain Credit Agreement dated as of January 12, 2024, by and among the Borrower, the other Loan Parties party thereto, Silver Point Finance, LLC, as the administrative agent thereunder and the Lenders party thereto (as amended, restated, amended and restated, supplemented or otherwise modified from time to time prior to the date hereof, the “Existing Credit Agreement”, and the Existing Credit Agreement, as amended by this Amendment, the “Credit Agreement”; capitalized terms used in this Amendment, to the extent not otherwise defined herein, shall have the same meanings as in the Credit Agreement);

…

**RESTRICTIVE COVENANT, CONFIDENTIALITY AND INVENTIONS AGREEMENT **

This Restrictive Covenant, Confidentiality and Inventions Agreement (“Agreement”) is made and entered into effective as October 12, 2026, by and between Henry Schein, Inc., a Delaware corporation headquartered in New York (the “Company”) and Emmanuel Caprais (“Employee”).

***RECITALS ***

WHEREAS, Employee is being offered employment by the Company in the key role of Senior Financial Advisor, transitioning to Senior Vice President, Chief Financial Officer, and the projected responsibilities of this role include, among others, providing strategic and financial leadership for the Company, overseeing the Company’s global finance organization and financial strategy, planning, reporting, controls and capital allocation, partnering with senior leadership to drive financial performance and long-term value creation, and supporting the Company’s strategic priorities and overall business objectives; and

…

October 6, 2026

Emmanuel Caprais

Dear Emmanuel:

On behalf of Henry Schein, Inc. (the “Company”), this letter will serve to confirm our offer to you. Your anticipated start date will be October 12, 2026. You will initially serve in the position of Senior Financial Advisor. Effective November 4, 2026 (the “Transition Date”), you will transition to the position of Senior Vice President, Chief Financial Officer. You will report to Frederick Lowery, Chief Executive Officer (or his successor), in both positions. Both of these positions will be based out of Melville, New York. Please respond to this offer within three business days.

Below I have outlined the compensation and benefit components of our offer:

…

**SECURITIES PURCHASE AGREEMENT **

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of October 7, 2026, by and among Atrium Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”).

WHEREAS, the Company and the Investors are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section 4(a)(2) of the Securities Act;

…

**REGISTRATION RIGHTS AGREEMENT **

THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of October 7, 2026, is entered into by and among Atrium Therapeutics, Inc.,** **a Delaware corporation (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Securities Purchase Agreement by and among the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”).

**WHEREAS: **

…